Understand evidence levels
Identify the model, study design, population and endpoint before accepting a benefit claim.
Understand peptide research through source-linked compound guides, evidence records and analytical references.
Open CalculatorFind the source, check the exact compound and understand the limits.
Peptides are short chains of amino acids that act as signaling molecules in the body. Unlike proteins, peptides are small enough to penetrate tissues rapidly and bind to specific receptors with high affinity.
Peptides regulate nearly every biological process — from metabolism and immune response to tissue repair and hormone secretion. Targeted peptide research has opened new frontiers in therapeutic science.
Explore research with the study model, exact compound and limitations kept visible. Start with the Evidence Finder, then follow the original source.
Compound identities, selected study findings and the limits of the evidence. Refreshed guides link directly to primary sources.
Human BPC-157 reports exist, but the studies examined here are small and uncontrolled. They do not establish reliable clinical benefit, long-term safety or equivalence between formulations and routes.
View GuideSemaglutide has randomized human evidence for weight management and, in a defined population, cardiovascular risk reduction. Route, formulation, indication and trial population remain essential to interpreting those results.
View GuideTirzepatide is a dual GIP/GLP-1 receptor agonist with large randomized human trials. Evidence for specified prescription products should not be transferred to unverified vials or self-directed treatment schedules.
View GuideRetatrutide targets GIP, GLP-1 and glucagon receptors. Randomized human studies show substantial weight reductions, but trial results do not establish the identity, safety or efficacy of online research products.
View GuideTB-500 is not a sufficiently precise identity on its own. A primary analytical paper identified acetylated LKKTETQ in one product; that does not make every TB-500 product equivalent to full-length thymosin beta-4.
View GuideHuman studies of long-acting CJC-1295 measured growth-hormone and IGF-I responses. They do not establish equivalent exposure for no-DAC products or demonstrate general anti-aging, muscle-building or fat-loss benefits.
View GuideIpamorelin can stimulate GH under studied conditions. Human pharmacology and postoperative research do not establish a general anti-aging, sleep, muscle or fat-loss treatment, and preclinical selectivity is not a human safety guarantee.
View GuidePT-141 is bremelanotide, a melanocortin receptor agonist. Clinical evidence and the Vyleesi approval concern a defined formulation and population—not a general sexual-performance claim or every product sold under the molecule's name.
View GuideFoundational GHK-Cu papers include fibroblast culture and rat wound experiments. They support specific research observations, not blanket claims of human rejuvenation or systemic treatment benefit.
View GuideEpithalon has laboratory telomerase findings. Human reports using Epithalamin are not automatically trials of this defined tetrapeptide, and telomere changes do not establish longer or healthier human life.
View GuideSelank has published human research. Small active-comparator and imaging studies need to be read on their own terms, not converted into guaranteed anxiety relief, cognitive enhancement or a personal regimen.
View GuideDSIP has small human sleep experiments, not a uniformly positive clinical record. A controlled insomnia study found weak effects and no change in subjective sleep quality.
View GuideAOD-9604 has animal experiments and human development history. The key distinction is that promising mouse findings did not establish clinically useful weight loss in the larger oral human trial reviewed by FDA.
View GuideA small uncontrolled human report included BPC-157 with thymosin beta-4, but it does not establish that an unspecified BPC/TB-500 product is effective, safe or synergistic.
View GuideCagrilintide is a long-acting amylin analogue studied alone and with semaglutide. Human trial findings are substantial, but combination results cannot be assigned to cagrilintide alone or to an unverified blend.
View GuideDifferent endocrine pathways can motivate combination research, but they do not prove a CJC/ipamorelin blend is superior or safe. The first question is whether the CJC component is the albumin-binding study molecule or a separately identified no-DAC material.
View GuideGLOW is a marketed blend of GHK-Cu, BPC-157 and TB-500. Its component studies address different materials and models; they do not add up to a demonstrated clinical benefit from the finished three-component product.
View GuideA finished ipamorelin/tesamorelin blend needs its own identity, content, stability and clinical evidence. Published studies of the individual agents do not establish the mixture's efficacy, safe handling or an optimal ratio.
View GuideKisspeptin-10 can affect LH secretion under studied conditions, but responses differ by physiological context. Small hormone experiments are not proof of improved fertility, lasting testosterone benefit or a broadly safe personal regimen.
View GuideKLOW is a marketed blend name, not a single peptide or a demonstrated weight-loss treatment. Start with the ingredient list and the exact molecules before drawing conclusions from research.
View GuideL-carnitine has human research and prescription uses, but neither supports treating every carnitine product as an established fat-loss intervention. The clearest reading separates the molecule, formulation, route, population and outcome.
View GuideLIPO-C is a formulation name, not a single peptide. The Heritage listing describes a methionine–inositol–choline solution; biochemical roles of those ingredients do not by themselves establish a weight-loss benefit from the mixture.
View GuideLL-37 has human topical wound studies, including a larger trial without significant overall healing benefit. Its normal biological role does not establish that external administration is uniformly beneficial or safe.
View GuideThe selected MOTS-c papers describe cells, mouse interventions and endogenous human measurements. They do not establish the efficacy of administered native MOTS-c in people; CB4211 is a separately named investigational intervention.
View GuideNAD+ is a coenzyme, not a peptide. Small human infusion studies describe metabolite handling and tolerability; they do not establish general rejuvenation, disease treatment or long-term safety.
View GuideSemax has human and animal research, but brain imaging, rehabilitation outcomes and rodent neurotrophin measurements answer different questions. None justifies a universal cognitive-enhancement promise.
View GuideSermorelin has a specific pediatric and diagnostic history. The selected child-growth study and FDA's Geref record do not validate general adult rejuvenation claims or make every compounded or research formulation equivalent to the historical medicine.
View GuideSLU-PP-332 is an experimental small molecule, not a peptide. Its published preclinical findings do not establish a human exercise replacement, weight-loss regimen or safe personal dose.
View GuideSNAP-8 is acetyl octapeptide-3. Human research includes a multi-ingredient dissolving-microneedle patch, but that is not proof of isolated SNAP-8 efficacy or systemic injection safety.
View GuideTesamorelin has randomized clinical evidence and a specific approved-product context for excess abdominal fat in adults with HIV-associated lipodystrophy. That is not a general weight-loss indication.
View GuideBacteriostatic water is a preserved diluent, not a universal peptide formulation. The exact product label, compatible material, container and intended use determine what can be concluded about a preparation.
View GuideA clear solution is not proof of a stable or injectable preparation. Acetic acid can be part of a particular laboratory formulation, but solvent choice and storage conditions must be validated for the exact material.
View GuideLyophilized peptides require precise reconstitution with bacteriostatic water. The ratio of solvent to peptide determines your concentration — and every downstream calculation depends on getting this right.
A reported exposure belongs with its study model, route, formulation and measured endpoint. It is not a personal dosing recommendation.
Understanding how concentration translates to syringe units on a 100-unit insulin syringe eliminates waste. Our calculator does this math instantly — so every vial is used efficiently.
Calculate injection volumes, syringe units, and doses per vial based on your reconstitution parameters.
Enter your reconstitution variables below.
Calculated values update in real time.
Mechanisms, laboratory tests and clinical outcomes answer different questions.
Identify the model, study design, population and endpoint before accepting a benefit claim.
Separate identity, purity, content and microbiological tests without treating one result as all of them.
Keep registration, recruitment, results and publication distinct. Follow the study identifier to the source.
Compound guides link directly to the studies they discuss and distinguish laboratory observations, animal experiments and clinical findings.
Follow the original study to inspect its methods, results and limitations. Product documentation and clinical research answer different questions.
Follow the original paper from each guide, explore related studies in the Evidence Finder, or contact the publication with a factual correction.
Peptide Mag is a publication about peptides and related research compounds. Its reference library connects accessible explanations with primary papers, trial records and analytical context.
Our goal is straightforward: provide accurate, well-sourced reference material without the noise. Just research data, clearly presented.
Peptide Mag explains research through compound guides, primary papers and analytical references. It does not provide personal treatment protocols.